Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07074418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Study acronym: EMPA[10-20]
StatusRecruiting
PhasePhase 4
Started2026-08-25
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Dec 2027 → May 2028
See other at-risk trials from Centre Hospitalier Universitaire de Nice

Amendment history

2026-09-08
Study Status, Eligibility, Contacts/Locations v3
Recruitment opened
Start dateestimated 2026-09→confirmed 2026-08-25
Eligibility criteria+272 characters
[...] dosage of antihypertensive drugs and diuretics for 1 month. for women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed. Exclusion Criteria: any medical condition that, in the opini [...]
Study sitesdetails revised at 1 of 1 site
2026-07-24
Study Status v2
Primary completion pushed: 2027-12 → 2028-05
Completion pushed: 2027-12 → 2028-05
Start date2026-04→2026-09
2026-01-21
Study Status v1
Primary completion date2027-08→2027-12
Completion date2027-08→2027-12
Start date2025-12→2026-04
2025-07-10
Original filing
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Trial Details
NCT Number NCT07074418
Lead Sponsor Centre Hospitalier Universitaire de Nice
Collaborators: Boehringer Ingelheim
Conditions Chronic Kidney Diseases
Enrollment 34 participants
Start Date 2026-08-25
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-09-10